New drug combo shows promise for tough head and neck cancers

NCT ID NCT03818061

Completed Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated May 15, 2026 · Updated 3 times

Summary

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 33 adults with advanced head and neck cancer that had already been treated with chemotherapy. The goal was to see if the combination could shrink tumors or stop the cancer from growing. The study was completed and focused on measuring how many patients responded to the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Léon Bérard

Lyon, 69373, France
Centre Paul Strauss

Strasbourg, 67065, France
Clinique Mutualiste de l'Estuaire

Saint-Nazaire, 44606, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Curie

Paris, 75005, France

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK NEOPLASMS